Pharmacokinetics and Dosing Recommendations of Tenofovir Disoproxil Fumarate in Hepatic or Renal Impairment

被引：0
|
作者：
Brian P. Kearney
Kitty Yale
Jaymin Shah
Lijie Zhong
John F. Flaherty
机构：
[1] Gilead Sciences Inc.,
来源：
Clinical Pharmacokinetics | 2006年 / 45卷
关键词：
Fumarate; Tenofovir; Hepatic Impairment; Tenofovir Disoproxil Fumarate; Severe Renal Impairment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: Tenofovir disoproxil fumarate is the prodrug of the acyclic nucleotide reverse transcriptase inhibitor tenofovir that is indicated for use in the treatment of HIV. Tenofovir is eliminated as unchanged drug in the urine, with a significant component of active tubular secretion. The aim of this study was to evaluate the pharmacokinetics of tenofovir in subjects with renal or hepatic impairment, both of which are common in HIV-infected individuals.
引用
收藏
页码：1115 / 1124
页数：9
相关论文
共 50 条
  • [41] Incidence of proximal renal tubular dysfunction in patients on tenofovir disoproxil fumarate
    Quinn, K. J.
    Emerson, C. R.
    Dinsmore, W. W.
    Donnelly, C. M.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2010, 21 (02) : 150 - 151
  • [42] Tenofovir disoproxil fumarate: profile report
    Tony Antoniou
    Anil Kumar
    Drugs & Therapy Perspectives, 2004, 20 (3) : 4 - 6
  • [43] COMPARATIVE PHARMACOKINETICS AND TOLERABILITY PROFILES OF TENOFOVIR DISOPROXIL OROTATE (DA-2802) AND TENOFOVIR DISOPROXIL FUMARATE (VIREAD®) IN HEALTHY SUBJECTS.
    Kim, E.
    Oh, J.
    Kim, Y.
    Chung, I.
    Jang, I-J
    Yu, K-S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S69 - S69
  • [44] Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate
    Liang, Lilian Yan
    Yip, Terry Cheuk-Fung
    Lai, Jimmy Che-To
    Lam, Amy Shuk-Man
    Tse, Yee-Kit
    Hui, Vicki Wing-Ki
    Chan, Henry Lik-Yuen
    Wong, Vincent Wai-Sun
    Wong, Grace Lai-Hung
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (09) : 4440 - 4448
  • [45] Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
    Bukkems, Vera E.
    Smolders, Elise J.
    Jourdain, Gonzague
    Burger, David M.
    Colbers, Angela P.
    Cressey, Tim R.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (03): : 388 - 393
  • [46] Combination Therapy Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Associated with Hepatic Failure
    Qayyum, Sohail
    Dong, Huijun
    Kovacic, Dianne
    Sohail, Sidra
    Waters, Bradford
    Thornton, Camille
    Corbett, Cathy E.
    CURRENT DRUG SAFETY, 2012, 7 (05) : 391 - 393
  • [47] Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation
    Shao-Ming Chiu
    Kuo-Chin Chang
    Tsung-Hui Hu
    Chao-Hung Hung
    Jing-Houng Wang
    Sheng-Nan Lu
    Chien-Hung Chen
    Digestive Diseases and Sciences, 2023, 68 : 665 - 675
  • [48] Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation
    Chiu, Shao-Ming
    Chang, Kuo-Chin
    Hu, Tsung-Hui
    Hung, Chao-Hung
    Wang, Jing-Houng
    Lu, Sheng-Nan
    Chen, Chien-Hung
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (02) : 665 - 675
  • [49] A randomized, open-label, crossover study to compare the safety and pharmacokinetics of two tablet formulations of tenofovir (tenofovir disoproxil and tenofovir disoproxil fumarate) in healthy subjects
    Yun, Jae Nam
    Yeun, Ji-Sun
    Kan, Hye-Su
    Lee, Minyu
    Kim, Namsick
    Oh, Tae-Young
    Nam, Seung-Kwan
    Choi, Yoon Seok
    Kwon, In Sun
    Hoe, Kwang Lae
    Hong, Jang Hee
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (12) : 749 - 756
  • [50] Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
    De Clercq, Erik
    BIOCHEMICAL PHARMACOLOGY, 2016, 119 : 1 - 7
12345